K G Castro1, S M Marks2, M P Chen2, A N Hill2, J E Becerra2, R Miramontes2, C A Winston2, T R Navin2, R H Pratt2, K H Young2, P A LoBue2. 1. The Hubert Department of Global Health, and Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 2. Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Abstract
BACKGROUND: Following a concerted public health response to the resurgence of tuberculosis (TB) in the United States in the late 1980s, annual TB incidence decreased substantially. However, no estimates exist of the number and cost savings of TB cases averted. METHODS: TB cases averted in the United States during 1995-2014 were estimated: Scenario 1 used a static 1992 case rate; Scenario 2 applied the 1992 rate to foreign-born cases, and a pre-resurgence 5.1% annual decline to US-born cases; and a statistical model assessed human immunodeficiency virus and TB program indices. We applied the cost of illness to estimate the societal benefits (costs averted) in 2014 dollars. RESULTS: During 1992-2014, 368 184 incident TB cases were reported, and cases decreased by two thirds during that period. In the scenarios and statistical model, TB cases averted during 1995-2014 ranged from approximately 145 000 to 319 000. The societal benefits of averted TB cases ranged from US$3.1 to US$6.7 billion, excluding deaths, and from US$6.7 to US$14.5 billion, including deaths. CONCLUSIONS: Coordinated efforts in TB control and prevention in the United States yielded a remarkable number of TB cases averted and societal economic benefits. We illustrate the value of concerted action and targeted public health funding.
BACKGROUND: Following a concerted public health response to the resurgence of tuberculosis (TB) in the United States in the late 1980s, annual TB incidence decreased substantially. However, no estimates exist of the number and cost savings of TB cases averted. METHODS: TB cases averted in the United States during 1995-2014 were estimated: Scenario 1 used a static 1992 case rate; Scenario 2 applied the 1992 rate to foreign-born cases, and a pre-resurgence 5.1% annual decline to US-born cases; and a statistical model assessed human immunodeficiency virus and TB program indices. We applied the cost of illness to estimate the societal benefits (costs averted) in 2014 dollars. RESULTS: During 1992-2014, 368 184 incident TB cases were reported, and cases decreased by two thirds during that period. In the scenarios and statistical model, TB cases averted during 1995-2014 ranged from approximately 145 000 to 319 000. The societal benefits of averted TB cases ranged from US$3.1 to US$6.7 billion, excluding deaths, and from US$6.7 to US$14.5 billion, including deaths. CONCLUSIONS: Coordinated efforts in TB control and prevention in the United States yielded a remarkable number of TB cases averted and societal economic benefits. We illustrate the value of concerted action and targeted public health funding.
Authors: A S Dharmadhikari; M Mphahlele; K Venter; A Stoltz; R Mathebula; T Masotla; M van der Walt; M Pagano; P Jensen; E Nardell Journal: Int J Tuberc Lung Dis Date: 2014-09 Impact factor: 2.373
Authors: Julia del Amo; Santiago Moreno; Heiner C Bucher; Hansjakob Furrer; Roger Logan; Jonathan Sterne; Santiago Pérez-Hoyos; Inma Jarrín; Andrew Phillips; Sara Lodi; Ard van Sighem; Wolf de Wolf; Caroline Sabin; Loveleen Bansi; Amy Justice; Joseph Goulet; José M Miró; Elena Ferrer; Laurence Meyer; Rémonie Seng; Giota Toulomi; Panagiotis Gargalianos; Dominique Costagliola; Sophie Abgrall; Miguel A Hernán Journal: Clin Infect Dis Date: 2012-03-28 Impact factor: 9.079
Authors: N J Binkin; A A Vernon; P M Simone; E McCray; B I Miller; C W Schieffelbein; K G Castro Journal: Int J Tuberc Lung Dis Date: 1999-08 Impact factor: 2.373
Authors: Mark N Lobato; Yong-Cheng Wang; Jose E Becerra; Patricia M Simone; Kenneth G Castro Journal: Public Health Rep Date: 2006 Mar-Apr Impact factor: 2.792
Authors: Suzanne M Marks; Jennifer Flood; Barbara Seaworth; Yael Hirsch-Moverman; Lori Armstrong; Sundari Mase; Katya Salcedo; Peter Oh; Edward A Graviss; Paul W Colson; Lisa Armitige; Manuel Revuelta; Kathryn Sheeran Journal: Emerg Infect Dis Date: 2014-05 Impact factor: 6.883
Authors: K G Castro; S M Marks; A N Hill; M P Chen; R Miramontes; C A Winston; P A LoBue Journal: Int J Tuberc Lung Dis Date: 2017-01-01 Impact factor: 2.373
Authors: Suzanne M Marks; David W Dowdy; Nicolas A Menzies; Priya B Shete; Joshua A Salomon; Andrea Parriott; Sourya Shrestha; Jennifer Flood; Andrew N Hill Journal: Public Health Rep Date: 2020 Jul/Aug Impact factor: 2.792
Authors: Nicolas A Menzies; Ted Cohen; Andrew N Hill; Reza Yaesoubi; Kara Galer; Emory Wolf; Suzanne M Marks; Joshua A Salomon Journal: Am J Epidemiol Date: 2018-09-01 Impact factor: 4.897
Authors: Sarah T Cherng; Sourya Shrestha; Sue Reynolds; Andrew N Hill; Suzanne M Marks; Jane Kelly; David W Dowdy Journal: Am J Public Health Date: 2018-11 Impact factor: 9.308
Authors: Nicolas A Menzies; Andrea Parriott; Sourya Shrestha; David W Dowdy; Ted Cohen; Joshua A Salomon; Suzanne M Marks; Andrew N Hill; Carla A Winston; Garrett R Asay; Pennan Barry; Adam Readhead; Jennifer Flood; James G Kahn; Priya B Shete Journal: Am J Respir Crit Care Med Date: 2020-02-01 Impact factor: 21.405